The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).
P. Lara
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
J. Douillard
Consultant or Advisory Role - Novartis
Honoraria - Novartis
K. Nakagawa
Consultant or Advisory Role - Novartis
J. Von Pawel
Consultant or Advisory Role - Antisoma; Novartis
M. J. McKeage
Consultant or Advisory Role - Antisoma; Novartis
Honoraria - Antisoma; Novartis
Research Funding - Antisoma; Novartis
I. Albert
No relevant relationships to disclose
G. Losonczy
No relevant relationships to disclose
M. Reck
Consultant or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Roche
D. S. Heo
No relevant relationships to disclose
X. Fan
Employment or Leadership Position - Novartis
A. Fandi
Employment or Leadership Position - Novartis
G. Scagliotti
Honoraria - AstraZeneca; Lilly; Roche